A phase III study of the conversion efficacy and safety of repeated intravenous doses of RSD1235 in subjects with atrial fibrillation or atrial flutter following valvular and/or coronary artery bypass graft surgery

Trial Profile

A phase III study of the conversion efficacy and safety of repeated intravenous doses of RSD1235 in subjects with atrial fibrillation or atrial flutter following valvular and/or coronary artery bypass graft surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2010

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-2; ACT-II
  • Most Recent Events

    • 02 Sep 2010 Vernakalant has been approved in the EU, Iceland and Norway based on the results of ACT-I, -II and -III and AVRO trials, according to a Merck media release.
    • 07 Nov 2007 Primary endpoint results have been presented
    • 04 Jun 2007 Status changed from 'recruiting' to 'completed'
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top